Azienda Ospedaliera Niguarda Cà Granda
13
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
15.4%
2 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Role: collaborator
Vinorelbine in Advanced BRAF-like Colon Cancer
Role: collaborator
Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart Failure
Role: collaborator
Rapamycin Treatment for ALS
Role: collaborator
The Relationship Between Belief, Expectation, and Adherence to Therapy During COVID-19 Pandemic
Role: collaborator
Laparoscopic Donor Nephrectomy Score, a New Scoring System for Preoperative Prediction of Difficulty of Laparoscopic Donor Nephrectomy
Role: collaborator
Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV
Role: collaborator
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Role: collaborator
Early Allograft Failure Simplified Estimation (EASE) in Liver Transplantation
Role: collaborator
EMR-C VS EMR-S in Colonic Lateral Spreading Tumors Treatment (LST)
Role: collaborator
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
Role: collaborator
Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Role: collaborator
Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
Role: collaborator
All 13 trials loaded